Patent ID: 8012465

Claim:
A method for treating a human patient having renal cell carcinoma, the method comprising: a) first, administering a dose of 18 MIU of an IL-2 mutein per day for 5 days during one week; b) second, administering a dose of 9 MIU of the IL-2 mutein per day for 2 days followed by administering a dose of 18 MIU of the IL-2 mutein per day for 3 days during each week, repeated for 5 weeks; c) third, administering no IL-2 mutein for 3 weeks; d) fourth, administering a dose of 9 MIU of the IL-2 mutein per day for 5 days of each week, repeated for 6 weeks; and e) fifth, administering no IL-2 mutein for 3 weeks, wherein said IL-2 mutein is administered by subcutaneous, intraperitoneal, intramuscular, intravenous, oral, pulmonary, nasal, topical, or transdermal administration, or by infusion or suppositories.